BPMC News and Press, Blueprint Medicines Corporation From 02/18/21

DCPH has seen some early success with ripretinib in 4th line and later GIST. However, the key to the mint is to show positive data in INTRIGUE, in 2nd line GIST for imatinib-refractory patients, and compared to sunitinib. That data will be out sometime in late 2021. For furt...

Blueprint Medicines ([[BPMC]] +8.3%) is trading higher today after the company shared updates on its clinical portfolio as part of the Q4 2020 earnings announcement.Cambridge, MA-based firm said that the FDA accepted its supplemental new drug application for AYVAKIT for advanced systemic...

Blueprint Medicines Corporation (BPMC) Q4 2020 Results Conference Call February 17, 2021 08:30 AM ET Company Participants Kristin Hodous - Senior Manager, IR Jeff Albers - CEO Christy Rossi - Chief Commercial Officer Fouad Namouni - President, Research and Development Mike Landsittel - CFO Co...

Blueprint Medicines  (BPMC): Q4 GAAP EPS of -$1.53 beats by $0.06.Revenue of $34.11M (-33.8% Y/Y) beats by $3.36M.Press Release For further details see: Blueprint Medicines  EPS beats by $0.06, beats on revenue

Blueprint Medicines Reports Fourth Quarter and Full Year 2020 Financial Results -- Supplemental NDA accepted by FDA for AYVAKIT™ (avapritinib) for advanced systemic mastocytosis -- -- Type II variation MAA submitted to EMA for AYVAKYT® (avapritinib) for advanced ...

BPMC's avapritinib is in post-NDA stage in systemic mastocytosis. Novartis' Rydapt is approved in this indication. However, there are key competitive differences favoring avapritinib. For further details see: Blueprint's Avapritinib In Systemic Mastocytosis: A Comparativ...

Blueprint Medicines  (NASDAQ:BPMC) is scheduled to announce Q4 earnings results on Wednesday, February 17th, before market open.The consensus EPS Estimate is -$1.59 and the consensus Revenue Estimate is $30.75M (-40.3% Y/Y).Over the last 1 year, BPMC has beaten EPS estimates 25% of the t...

[[ADI]], [[ALE]], [[ATH]], [[BCOR]], [[BPMC]], [[CHH]], [[COMM]], [[CRL]], [[DAVA]], [[DNOW]], [[EQT]], [[FUN]], [[GPC]], [[GRMN]], [[HEES]], [[HLT]], [[HSIC]], [[IRWD]], [[NI]], [[OC]], [[RPRX]], [[SAH]], [[SFL]], [[SHOP]], [[WING]], [[WIX]]For Seeking Alpha's full earnings season calendar, ...

Blueprint Medicines to Report Fourth Quarter and Full Year 2020 Financial Results on Wednesday, February 17, 2021 PR Newswire CAMBRIDGE, Mass. , Feb. 10, 2021 /PRNewswire/ -- Blueprint Medicines Corporation (NASDAQ: BPMC), a precision therapy company focused...

Blueprint Medicines ([[BPMC]] -1.1%) promoted Andy Boral, M.D., Ph.D. to EVP, Clinical Development from his current chief medical officer position.Becker Hewes, M.D. will be named chief medical officer.Marion Dorsch, Ph.D., Chief Scientific Officer, has resigned from the company, ef...